- Home
- MMA vs GTBP Comparison
MMA vs GTBP Comparison
Compare MMA & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | GTBP |
|---|---|---|
| Founded | 2013 | 1965 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 12.4M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MMA | GTBP |
|---|---|---|
| Price | $0.33 | $3.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 69.3K |
| Earning Date | 11-06-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.22 |
| 52 Week High | $1.49 | $236.00 |
Technical Indicators
Market Signals| Indicator | MMA | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 28.32 |
| Support Level | $0.25 | $0.22 |
| Resistance Level | $0.42 | $7.50 |
| Average True Range (ATR) | 0.05 | 0.39 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 45.25 | 4.37 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.